FDA Sharply Restricts Avandia Use

A diabetes drug linked with a higher risk of heart attack will be sharply restricted starting November 18. The drug is rosiglitazone (Avandia). Nearly a year ago, a group of experts recommended that the drug be pulled from the market or remain with tighter limits. The U.S. Food and Drug Administration (FDA) imposed some new rules in September. It announced the full new policy this week. Avandia will be pulled from pharmacy shelves. It will be available only through specific mail-order pharmacies. Doctors will have to be certified in order to prescribe it. The drug will be limited to patients who are doing well on it now or can’t control their blood sugar with other drugs. They must be informed of the risks and choose to take Avandia anyway. The policies also apply to Avandamet and Avandaryl. These pills combine rosiglitazone with other diabetes drugs.